“If you are looking for a PCR-based focused assay, then ddPCR is perfect. It’s faster and cheaper, and it is the most robust method of achieving an answer.  ddPCR is the ‘best in class’, because it is quantitative, extremely sensitive, and shows very high specificity. This is why the technology has become our ‘go-to’ PCR assay for both plasma cell-free DNA and tumor DNA genotyping.”

– DR. GEOFFREY OXNARD, SELECTSCIENCE INTERVIEW, AUGUST 2017.

Platform Overview

Droplet Digital PCR (ddPCR™) is a highly sensitive form of PCR that is based on the partitioning of DNA into droplets. It is a highly precise technology platform that has been recently optimized in oncology for clinical analysis of cell-free DNA (cfDNA) and cell-free RNA (cfRNA) in plasma to detect targeted tumor mutations and translocations. Biodesix uses the Bio-Rad QX200 ddPCR system and QuantaSoft Software for data analysis.

Key Benefits of ddPCR™

BLOOD OR TISSUE

FAST PROJECT TURNAROUND

CUSTOM DESIGNED ASSAYS

HIGHLY ACCURATE

PMA READY QMS

The GeneStrat® Test

The GeneStrat® test is Biodesix’s on-market liquid biopsy test using ddPCR to analyze cfDNA and cRNA. The GeneStrat test delivers actionable, blood-based results within 72 hours for patients with NSCLC from a simple blood draw. The GeneStrat test covers actionable mutations in the following genes: EGFR (sensitizing and resistance), ALK, ROS1, RET, KRAS, and BRAF.

Custom Assay Development

Biodesix develops custom blood-based assays based on your individual needs. We offer a menu of ddPCR mutation detection assays, and design multiplexed assays, to help with targeting in your drug development programs. Partners use our tests for preclinical biomarker work, retrospective analyses, clinical study enrollment, and coordinated commercial deployment. Biodesix can analytically and clinically validate ddPCR assays in our CLIA/CAP/CLEP/ISO certified laboratory.

Get in touch

Contact us